Breast-conserving therapy may be option for multiple breast lesions

Elacestrant shows improved PFS in ER-positive/HER2-negative mBC

T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable and/or mBC previously treated with T-DM1

Breast cancer patients who interrupted endocrine therapy to pursue pregnancy did not have worse short-term recurrence rates

Comment: POLAR gene profile can identify which patients can safely avoid radiation therapy after breast-conserving surgery

Updates from TAILORx and RxPONDER: Implications for practice

Interruption of endocrine therapy in young breast cancer patients does not increase the risk of short-term relapse

Genetic profiling identifies patients who can omit radiation therapy after breast-conserving surgery

A genomic assay may predict long-term prognosis in premenopausal patients with HR+ early-stage breast cancer

Trastuzumab deruxtecan shows greater OS compared to trastuzumab emtansine in patients with HER2 + mBC

Adjuvant endocrine therapy +/- 1 year of everolimus fails to improve iDFS and OS in patients with high-risk HR+, HER2-negative BC

Camizestrant may be superior to fulvestrant in patients with hormone receptor-positive, HER2-negative breast cancer

Opinion: Premature regulatory approval by the FDA

Addition of platinum to standard neoadjuvant chemotherapy improves EFS in patients with TNMBC

HER2DX confirms the ability of the test to predict long-term survival and response to anti-HER2 therapy in BC

Treatment decision guided by CTC count may improve long-term outcomes for mBC